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Abstract: Neurofilament protein alterations are found in many neurodegenerative diseases, such as amyotrophic lateral 
sclerosis, Parkinson, Alzheimer, and Charcot-Marie-Tooth. Abnormal modifications of neurofilament, such as mutation, 
oxidation and phosphorylation, are linked to the disease-related alteration. In this review, the most recent discovery and 
central arguments about functions, pathological modifications, and genetic mutations related to neurofilaments in neu-
rodegenerative diseases is presented. 
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INTRODUCTION 
Neurofilaments are intermediate filaments in neurons 
composed of three subunits, NFH, NFM, and NFL (Neuro-
filament heavy, medium, and light subunits). Primarily ex-
pressed in neurons, neurofilament proteins are major compo-
nents in large myelinated axons, e.g. sciatic and optic nerves.  
Abnormal accumulation of neurofilament is a primary find-
ing in many human neurodegenerative disorders, including 
amyotrophic lateral sclerosis, Parkinson, Alzheimer, Char-
cot-Marie-Tooth, dementia with Lewy bodies [1, 2], and 
toxic neuropathy [3]. Many alterations can potentially lead to 
accumulation of neurofilaments, including mutation, dis-
regulation of neurofilament protein synthesis, defective ax-
onal transport, and abnormal phosphorylation/glycosylation/ 
oxidation [4]. Neurofilament abnormality in neurodegenera-
tive disorders is a hallmark of neuronal dysfunction, espe-
cially marking axonal degeneration.  
Amyotrophic Lateral Sclerosis (ALS) 
A major pathological hallmark of ALS is intraneuronal 
accumulation of phosphorylated neurofilament proteins in 
degenerating motor neurons [5-7]. The neurofilament protein 
accumulations are characterized by forming initially in the 
distal axon and retrogradly transported to the cell body, cor-
related with severity of disease.  Neurofilament gene expres-
sion patterns are altered in ALS, suggesting NF subunit ratio 
could be important [8]. 
Singly overexpressing any of the neurofilament subunits 
(NFL, NFM or NFH) in transgenic mice led to prominent  
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motor neuropathy characterized by the presence of abnormal 
neurofilament accumulations resembling those found in ALS 
[9-11]. Restoring a correct stoichiometry of human NFL to 
NF-H subunits with the co-expression of human NFL trans-
gene in transgenic mice overexpressing human NFH rescues 
the motor neuropathy [12]. Similar changes in stoichometry 
may occur in diseases as NFL mRNA is selectively reduced 
by up to 70% in degenerating neurons of ALS and AD [13, 
14].  
Codon deletions or insertions in the KSP regions of NFH 
have been detected in a small number of sporadic cases of 
ALS, including a large deletion of five KSP repeats [15-17].  
Studies by Lobsiger and colleagues [18] showed genetic 
elimination of NFM and NFH tail domains and their 58 
known phosphorylation sites in SOD1 mutant mice acceler-
ates aberrant phosphorylation of other neuronal substrates 
while leaving overall neurofilament content unaltered. The 
disease onset is significantly delayed and survival is ex-
tended in mice, which indicates that abnormal phosphoryla-
tion may be a detrimental factor. 
Studies by Ludemann et al., [19] showed that in spinal 
cord tissue of a transgenic rat model for ALS, O-linked N-
acetylglucosamine immunoreactivity of neurofilament pro-
teins is strongly decreased compared with wild-type animals 
while phosphorylation is increased, suggesting competition 
of the binding sites of these two modifications and a poten-
tial mechanism for the formation of neurofilament protein 
accumulations in ALS. 
Pin1 associates with phosphorylated NFH in neurons and 
is colocalized in ALS-affected spinal cord neuronal inclu-
sions [20]. Inhibition of Pin1 activity by inhibitor or down-
regulating Pin1 levels through siRNA rescued neurons from 
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glutamate-induced cell death. The authors suggest that Pin1 
inhibition may be a therapeutic target to reduce pathological 
accumulations of p-NFH 
More recently, the possible involvement of dynein/  
dynactin in ALS has also been explored.  Teuling and col-
leagues [21] generated transgenic mice with neuron specific 
expression of Bicaudal D2 N-terminus (BICD2-N) to 
chronically impair dynein/dynactin function and their results 
showed that BICD2-N mice did not develop signs of motor 
neuron degeneration and motor abnormalities even with ap-
parent abnormalities. Also this transgene increased life span 
in SOD1-G93A ALS transgenic mice.  They concluded that 
impaired dynein/dynactin function may be part of the ALS 
phenotype although further work is clearly called for to clar-
ify the mechanism. 
Cheroni and colleagues [22] demonstrated impairment of 
the ubiquitin proteasome system (UPS) in lumbar spinal cord 
in double transgenic mice expressing the familial ALS su-
peroxide dismutase 1 (SOD1) gene mutation G93A 
(SOD1G93A). They showed that one third of the cells with 
accumulation of the UPS reporter substrate also displayed an 
accumulation of phosphorylated neurofilaments (SM1-31), 
like those normally present only in axons. In line with this, 
they report that not all the ventral horn neurons showing re-
porter gene immunoreactivity also accumulated phosphory-
lated neurofilaments or ubiquitin, two markers of degenera-
tion in ALS. 
The possibility that not only post-translational changes of 
NF subunits are promoting neurofilamentopathy has also 
been addressed.  Volkening and colleagues [23] examined 
the interactions of TDP-43, 14-3-3 and SOD1 proteins with 
NFL mRNA 3’UTR due to their potential to directly affect 
the stability of NFL transcripts. When ALS spinal cord mo-
tor neurons were assessed, it appeared that TDP-43 can be 
sequestered into translationally quiescent granules as either 
stress and degradative granules in a manner consistent with 
the relocalization of TDP-43 under neuronal stress. Their 
findings suggest that a greater proportion of NFL may be 
targeted for translational silencing and/or degradation in 
ALS.  Interestingly, mice lacking neurofilament expression 
show delayed disease onset from mutant SOD1 [24]. 
Brettschneider and colleagues [25] reported a 5-fold in-
crease of NFH level in CSF samples of ALS patients com-
pared to controls, suggesting NFH level can be a marker of 
axonal damage.  Kuhle and collaborators [26] validated a 
new electrochemiluminescence (ECL) immunoassay for the 
neurofilament heavy chain protein using SMI-35 antibody, 
showing that their ECL based assay resulted in superior sen-
sitivity, precision and accuracy, further opening the field to 
neurofilament-based biomarkers. 
Alzheimer Disease (AD)  
Neurofibrillary tangles, one of the hallmarks of AD, are 
composed of abnormally modified tau protein, plus neuro-
filament proteins, ubiquitin and other cytoskeleton proteins 
[27, 28]. Studies agree that tau protein and neurofilament 
proteins found in neurofibrillary tangles are extensively 
phosphorylated, especially in some sites not seen in the 
physiological state, which is likely due to perturbation in the 
balance between kinase and phosphatase activities [29-32].   
Neurofilament protein expression levels are altered in 
AD [33].  In addition, oxidative markers are highly concen-
trated in the lesions of AD and in neurofilament proteins of 
axons whether in AD or controls [34-36]. Pamplona and col-
leagues [36] showed elevation of all markers of oxidation, 
particularly those of reactive aldehydes from glycoxidation 
and lipoxidation that react with lysine residues on proteins in 
brain cortex samples from Alzheimer patients using GC-
mass spectrometry. Modifications involve neurofilaments, 
tubulin, and others.  
The presence of neurofilament proteins and their phos-
phorylation sites in neurites of senile plaques were also ex-
amined [37], where they show novel phosphorylation sites 
on NFL.  They suggest the complexity and possible role of 
the neurofilament in the formation of senile plaques. 
Deng and colleagues [38] demonstrated that O-
GlcNAcylation and phosphorylation of NFM regulate each 
other reciprocally in cultured neuroblastoma cells and in 
metabolically active rat brain slices. In animal models of 
fasting rats, they found a decrease in O-GlcNAcylation and 
increase in phosphorylation of NFM. They also observed 
decreased O-GlcNAcylation and an increased phosphoryla-
tion of NFM in AD brain. These results suggest that O-
GlcNAcylation and phosphorylation of NF-M were regulated 
reciprocally and that the hyperphosphorylation and accumu-
lation of NF-M in AD brain might be caused by impaired 
brain glucose uptake/metabolism via down-regulation of NF-
M O-GlcNAcylation.  
Björkdahl and colleagues [39] showed that overexpres-
sion of the chaperonin proteins Hsp27 or alphaB-crystallin in 
N2a cells could increase or decrease phosphorylation level of 
tau and NF. Expression of Hsp27 and alphaB-crystallin in 
AD brain samples were increased by 20% and 30% respec-
tively, which correlated significantly with phosphorylated 
tau and NF proteins. 
Using ELISA and antibodies to tau and NFH, Bret-
tschneider and colleagues [25] reported that NFH protein 
increased 10 fold in AD patient CSF samples compared to 
controls. They suggested that NFH level in CSF could be 
used as a marker for axonal damage, much as tau has been 
suggested as a marker for neuronal damage. 
The role of neurofibrillary tangles and senile plaques in 
AD is under intensive debate [40]. Some researchers believe 
that protein accumulation in various polymeric and mono-
meric forms is the initial cause of the disease, and others 
think such accumulation is the response to the initial insult, 
which results in different approaches in development of 
therapeutics. Significant protein accumulation is a response 
to oxidative damage occurring with aging, [35, 41]. There-
fore, preventing oxidative damage may provide a useful in-
tervention to reduce neurofilament protein abnormalities. 
Recently, Thangavel [42] and collaborators described a 
negative relation between SMI-32 immunoreactivity, non-
phosphorylated neurofilament, and AT8, an antibody against 
hyperphosphorylated tau, in specific brain areas. Neurons 
expressing non-phosphorylated neurofilaments in temporal 
cortical areas were susceptible to early degeneration in AD 
and the vulnerability of these SMI32 positive subpopulations 
of pyramidal cells in AD is associated with co-expression of 
abnormally phosphorylated tau protein, suggesting a com-
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plex interplay between tau and neurofilament phosphoryla-
tion [43, 44]. 
Knowing the distribution and co-localization of other 
neurofilament-related proteins is also important to under-
standing the neurofilamentopathy in AD. Sonoda and col-
leagues [45] demonstrated the phosphatase and tensin homo-
logue on chromosome 10 (PTEN), linked to AD, functions 
both as a tyrosine phosphatase and lipid phosphatase and is 
colocalized with abnormal tau and phosphorylated neuro-
filament proteins in neurons. These findings suggest that 
redistribution of PTEN to neuritic pathology may be signifi-
cant in the formation of tau and neurofilament pathology in 
AD brains. 
Parkinson Disease (PD) 
PD is marked by degeneration of the pigmented neurons 
in the substantia nigra resulting in decreased dopamine se-
cretion. Lewy bodies, the major pathological change of PD, 
and found in the degenerating neurons, are an inclusion 
composed of numerous proteins including -synuclein, three 
neurofilament subunits, ubiquitin and proteasome subunits, 
torsinA and parkin [46, 47], some of which are genetically 
linked to the disease [48-51]. 
A proteomic analysis of substantia nigra samples from 
PD patients showed reduced protein level of NFM and NFL 
in brain of PD patients, and an elevated oxidative-state cellu-
lar environment was also confirmed [52].  NFL mRNA is 
also decreased, correlating with the severity of the disease of 
PD [53]. 
An early onset (age 16) PD patient showed a point muta-
tion in the region of the NEFM gene coding for the rod do-
main 2B of NFM [54]. The base pair change results in sub-
stitution of serine for glycine at residue 336, and was argued 
to disrupt neurofilament assembly [55]. This NFEM gene 
mutation was screened in another 322 PD patients and none 
were found [56].  Han and colleagues [57] re-screened an 
additional 102 PD patients and 45 controls for this single 
base pair substitution (G1747A) mutation of the NFEM 
gene, which was reported by Lavedan and colleagues [54].  
No mutation was found. 
Abdo and colleagues [58] examined the differences of 
patients with idiopathic Parkinson's disease from patients 
with multiple system atrophy predominated by parkinsonism 
(MSA-P) using multiple protein markers. They showed that 
CSF levels of NFL, NFH, and tau were significantly in-
creased in MSA-P.  
Charcot-Marie-Tooth Disease (CMT)  
CMT is the most common inherited neurological disorder 
and it is generally inherited in an autosomal dominant pat-
tern. CMT affects both motor neurons and sensory neurons 
to the muscles, and patients slowly lose function of their 
feet/legs and hands/arms as nerves to the extremities degen-
erate.  
Several mutations of the NEFL gene on chromosome 8 
are associated with CMT2 including a proline to glutamine 
at residue 8, a proline-to-serine substitution at codon 22, 
leucine to proline at residue 333, leucine to proline at residue 
394 [59-64].  Jordanova and colleagues [62] also found six 
pathogenic missense mutations and one 3-bp inframe dele-
tion in the NFL gene in 323 patients with different CMT 
phenotypes.  
Recently, Sasaki and colleagues [65] showed that 
Pro22Ser mutations abolished Thr21 phosphorylation by 
cyclin-dependent kinase 5 and external signal regulated 
kinase, which suppressed filament assembly, but phosphory-
lation by protein kinase A (PKA) inhibited aggregate forma-
tion in vitro and alleviated aggregates in cortical neurons. 
These results indicate that the Pro22Ser CMT mutation in-
duces abnormal filament accumulation by disrupting proper 
oligomer formation and the aggregates are mitigated by 
phosphorylation with PKA, which makes it a viable target 
for the development of therapeutics. 
Further examination of three mutations in the NFL gene 
P22S, P8R, Q333P, in cell culture, [66] showed these muta-
tions affect the axonal transport of mutant and wild-type 
neurofilaments. They also affected the transport of mito-
chondria and human amyloid  protein precursor; resulting 
in alterations of retrograde axonal transport, fragmentation of 
the Golgi apparatus, and increased neuritic degeneration. 
Zhai and colleagues [67] investigated the role of aggrega-
tion of NFL protein in the neurotoxicity of CMT mutant 
NFL and CMT mutant HSPB1 in motor neurons, which 
cause neuron death. They found that expression of wild type 
HSPB1 could remediate the progressive degeneration and 
loss of neuronal viability.  Hull and colleagues [68], using a 
mouse muscle cell line expressing chimeric neurofilament 
(NF) proteins, found reduced cell viability and activated 
caspases, which mimic the pathology of CMT and may be a 
useful cell model for future studies to investigate the mecha-
nism responsible for NFL disruption.  These studies support 
the view that aggregation of NFL is a common triggering 
event of motor neuron degeneration in CMT. 
Moreover, Zhu and colleagues [69] described how both 
increases and decreases in the phosphorylation of neurofila-
ment network are modulated by multisynthetase complex 
p43 (MSC p43). Their results determine that overexpression 
of MSC p43 led to a decreased level of neurofilament protein 
phosphorylation, whereas MSC p43 depletion caused hyper-
phosphorylation of neurofilament proteins and neurofilament 
network disassembly in primary cultured neurons and motor 
axons.  Further assays using MSC p43-Null mice show simi-
lar phenotypic traits shared with CMT neuropathy type 2D, 
such as loss of large diameter axons from both motor and 
sensory peripheral nerves, distal motor neuropathy with im-
pairment in synaptic connectivity at neuro-muscular junc-
tions, and muscle denervation in the hind limb. 
The role of neurofilaments was further clarified by using 
double transgenic mice, hNF-L
P22S
; that model CMT2E [70]. 
They suggest CMT pathology is mostly unrelated to the NF 
accumulation in the cell bodies, as they found normal NF 
density in axons but instead decreased density of microtu-
bules. The effects of hNF-L
P22S 
could arise from cytoskeletal 
alterations that provoke axonal transport defects due to mi-
crotubule abnormalities.  These findings highlight the close 
interrelationship of cytoskeletal systems.  
SUMMARY 
Neurofilament abnormalities have been directly or indi-
rectly demonstrated in multiple neurodegerative diseases. 
Neurofilamentopathy in Neurodegenerative Diseases The Open Neurology Journal, 2011, Volume 5    61 
The removal of the protein aggregates with different ap-
proaches is an area of intense interest. In spite of whether 
these protein aggregates were the cause or the consequence 
of these diseases, neurofilament abnormalities are a critical 
factor in the cellular disruption in a number of neurodegen-
erative diseases. Understanding the characteristics, the 
mechanism of the formation, and approaches to modulate 
neurofilament abnormalities is central to monitoring and 
developing efficacious therapeutics. 
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